Seer
Seer's revenue rose 17.0% to $17 million in fiscal 2025. Its operating margin was −470.4%, up from −706.4% a year earlier. Free cash flow was −$46 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Seer lost money in fiscal 2025: a net loss of $74 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 493 | 426 | 373 | 300 | 241 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3,248.8x | — | — | — | — |
| Current ratio | 30.7x | 34.6x | 25.0x | 16.5x | 12.8x |
| Quick ratio | 30.4x | 34.2x | 24.7x | 16.0x | 12.3x |
Cash flow
Projections
Project Seer's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Seer says to expect
- Full year 2026: revenue
Seer now expects full-year 2026 revenue to be in the range of $13.5 million to $14.5 million, compared with the prior range of $16 million to $18 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Seer shares on the open market, and 4 insiders sold $117,931, $23,239 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Charles EndweissVP Financial Planning Analysis | Sold | 2,447 | $1.46 | $3,578 | Form 4 |
| Aug 18, 2026 | David R. HornPresident & CFO | Sold | 7,309 | $2.03 | $14,837 | Form 4 |
| Jul 8, 2026 | Dipchand NisharDirector | Sold plan | 10,660 | $2.18 | $23,239 | Form 4 |
| May 20, 2026 | David R. HornPresident & CFO | Sold | 7,303 | $1.69 | $12,342 | Form 4 |
| Feb 18, 2026 | Omid FarokhzadCEO and Chair, Director | Sold | 24,385 | $1.99 | $48,526 | Form 4 |
| Feb 18, 2026 | David R. HornPresident & CFO | Sold | 7,743 | $1.99 | $15,409 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −390.8% | −365.6% | −262.0% |
| Altman Z'' | 11.48 | 7.75 | 4.62 |
| Accruals ratio | −5.9% | −10.1% | −8.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Seer side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Seer | FY25 | 17.0% | −470.4% | −278.9% | — | — | — | |
| OmniAb | FY25 | −29.3% | −369.5% | −198.3% | — | — | — | Compare |
| Precipio | FY25 | 29.8% | −5.0% | 1.5% | −7.8% | −37.4x | 7 | Compare |
| Bionano Genomics | FY25 | −7.4% | −117.0% | −57.3% | −89.9% | — | 5 | Compare |
| MaxCyte | FY25 | −14.5% | −157.1% | −109.5% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1 | 7 | 16 | 17 | 14 | 17 |
| Revenue growth | — | 908.7% | 134.1% | 7.5% | −14.9% | 17.0% |
| Gross profit | 1 | 3 | 7 | 8 | 7 | 8 |
| Research and development | 19 | 29 | 46 | 53 | 51 | 44 |
| Operating income | −34 | −72 | −97 | −104 | −100 | −78 |
| Net income | −33 | −71 | −93 | −86 | −87 | −74 |
| Diluted EPS (US$) | −2.48 | −1.17 | −1.49 | −1.35 | — | — |
| Diluted shares (millions) | 13 | 61 | 62 | 64 | — | — |
| Cash flow | ||||||
| Cash from operations | −21 | −46 | −61 | −59 | −46 | −44 |
| Capital expenditure | 4 | 7 | 10 | 7 | 4 | 2 |
| Free cash flow | −25 | −53 | −71 | −66 | −50 | −46 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 26 | 34 | 34 | 28 | 15 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 432 | 493 | 426 | 373 | 300 | 241 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 442 | 539 | 488 | 436 | 367 | 296 |
| Total liabilities | 11 | 36 | 41 | 39 | 39 | 37 |
| Shareholders' equity | 432 | 503 | 447 | 397 | 328 | 259 |
| Margins and ratios | ||||||
| Gross margin | 100.0% | 51.6% | 45.8% | 51.0% | 49.8% | 51.1% |
| Operating margin | −5,129.4% | −1,080.1% | −627.6% | −621.0% | −706.4% | −470.4% |
| Net margin | −4,996.2% | −1,075.5% | −600.0% | −517.8% | −611.1% | −444.0% |
| Free cash flow margin | −3,866.2% | −805.0% | −458.6% | −398.4% | −350.7% | −278.9% |
| Rule of 40 (growth + FCF margin) | — | 103.7% | −324.4% | −390.8% | −365.6% | −262.0% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −15.2% | −19.6% | −20.4% | −23.9% | −25.1% |
| Return on assets | — | −14.5% | −18.1% | −18.7% | −21.6% | −22.2% |
| Net debt to EBITDA | — | — | — | — | — | — |